Skip to main content
Smart Investors Daily
Medtronic plc logo

NASDAQ · MDT

Medtronic plc

Healthcare · Medical - Devices

$93.75

Down-$0.05 (-0.05%)

Updated Sep 16, 2026, 11:18 AM

SID Score

6.5/10

Composite research score

Smart Money

34/100

Bearish

Market cap
127.94B
P/E ratio
26.83
Dividend yield
3.77%
52-week range
$73.31 – $105.50
Volume
7.15M
Avg. volume
7.16M

Price performance

MDT price history

1M range · 0 trading sessions · Daily adjusted prices

MDT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MDT news

The latest Smart Investors Daily articles mentioning MDT.

MDT research

Overview

Company profile and research snapshot.

Company profile

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$111.50
Implied upside
Analysts
22
MDT recent ratings
DateFirmRatingTarget
Sep 3, 2026UBSBuy
Sep 2, 2026Truist SecuritiesHold
Sep 2, 2026Wells FargoOverweight
Sep 2, 2026RBC CapitalOutperform
Sep 2, 2026B of A SecuritiesBuy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

MiniMed’s (MMED) New Pump Lineup Is Finally Winning Patients Over

On September 1, MiniMed (NASDAQ:MMED) reported its first full quarter as a stand-alone public company, and the numbers suggest the split from Medtronic is already paying off. Revenue jumped 15.8% to $843 million, and management raised its full-year growth outlook just months after the IPO roadshow. The catalyst is simple. A new pump finally shipped, […]

Yahoo · Sep 10, 2026

Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears

Jim Cramer called Medtronic plc (NYSE:MDT) a “quandary” on the September 8 episode of Mad Money, as he said: At the same time, there’s some tremendous healthcare companies in bull market mode… Here’s one that’s a quandary, Medtronic. Medtronic, the medical device company, shocked us with a big upside surprise and a major increase in […]

Yahoo · Sep 10, 2026

Medtronic’s (MDT) Heart Devices Are Suddenly Outgrowing The Rest Of Med-Tech

On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%. An extra selling week included in the quarter, which ended July 31, added roughly $570 million to that figure. Still, even stripping that out, management called it the strongest […]

Yahoo · Sep 9, 2026

Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?

Medtronic plc (NYSE:MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook. The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.